

***Pre-stems:
Suffixes used in the selection of INN
and their published INN
May 2018***

Programme on International Nonproprietary Names (INN)

Technologies Standards and Norms (TSN)

Regulation of Medicines and other health technologies (RHT)

***World Health Organization,
Geneva***

stem

definition

-suffix

-infix-

In bold: new pre-stems selected during the last Consultation.

-adenant

adenosine receptors antagonists

ciforadenant (118)

preladenant (99)(60)

tozadenant (106)(68)

vipadenant (103)(65)

-algron

α_1 -adrenoreceptor agonists

dabuzalgron (89)(51)

-ampator

α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor modulators

farampator (92)(54)

mibampator (103)(65)

tulrampator (116)(78)

-axomab

see *mab*

-becestat

see *stat*

-berel

beta estrogen receptor agonists

erteberel (104)(66)

prinaberel (95)(57)

-bresib

inhibitors of the bromodomain and extra-terminal motif
(BET) family of bromodomain (BRD) proteins, antineoplastics

alobresib (117)(79)

birabresib (115)(77)

mivebresib (115)(77)

molibresib (116)(78)

-caftor

cystic fibrosis transmembrane regulator (CFTR) protein
modulators

deutivacaftor (118)

10837 *galicaftor* (for 119)

ivacaftor (104)(66)

lumacaftor (105)(67)

10886 *olacaftor* (for 119)

tezacaftor (114)(76)

- <i>calcet/-calcet-</i>	calcium-sensing receptors (CaSR) agonists <i>cinacalcet</i> (88)(50) <i>etelcalcetide</i> (112)(74) <i>evocalcet</i> (113)(75) <i>tecalcet</i> (87)(49) <i>upacalcet</i> (118)
- <i>camra</i>	intracellular adhesion molecule (ICAM-1) derivatives <i>tremacamra</i> (78)(40)
- <i>casan</i>	caspase inhibitors <i>emricasan</i> (98)(60) <i>belnacasan</i> (108)(70) <i>nivocasan</i> (105)(67) <i>pralnacasan</i> (97)(47)
- <i>caserin</i>	serotonin receptor agonists (mostly 5-HT ₂) <i>lorcaserin</i> (95)(57) <i>vabicaserin</i> (95)(57)
- <i>catib</i>	cathepsin inhibitors <i>balicatib</i> (92)(54) <i>dutacatib</i> (94)(56) <i>odanacatib</i> (98)(60) <i>petesicatib</i> (117)(79) <i>relacatib</i> (95)(56)
- <i>cerfont</i>	corticotropin-releasing factor type-1 (CRF1) receptor antagonists <i>emicerfont</i> (102)(64) <i>pexacerfont</i> (97)(59) 10884 <i>tildacerfont</i> (for 119) <i>verucerfont</i> (102)(64)
- <i>closporin</i>	ciclosporin derivatives <i>ciclosporin</i> (47)(!) <i>geclosporin</i> (70)(34) <i>oxeclosporin</i> (70)(34) <i>ruclosporin</i> (114)(76) <i>voclosporin</i> (97)(59)
- <i>codar</i>	see <i>dar</i>
- <i>corat</i>	glucocorticoid receptor agonists <i>dagrocorat</i> (111)(73) <i>fosdagrocorat</i> (111)(73) <i>mapracorat</i> (102)(64) <i>tomicorat</i> (108)(70)
- <i>cridar</i>	see <i>dar</i>

- <i>dacin</i>	antibiotics, DNA gyrase and topoisomerase IV inhibitors <i>ardacin</i> (57)(!) <i>gepotidacin</i> (113)(74) <i>viqidacin</i> (98)(60) <i>zolidacin</i> (114)(76)
<i>dar</i>	<i>drugs used in multidrug resistance</i>
- <i>cridar</i>	acridinecarboxamide derivatives <i>elacridar</i> (76)(38)
- <i>codar</i>	pipecolinate derivatives <i>biricodar</i> (79)(40) <i>timcodar</i> (80)(42)
- <i>spodar</i>	ciclosporin D derivatives <i>valspodar</i> (76)(38)
- <i>depsin</i>	depsipeptide derivatives <i>elisidepsin</i> (101)(63) <i>plitidepsin</i> (93)(55) <i>romidepsin</i> (94)(56)
- <i>dil</i>	<i>vasodilators</i>
- <i>sudil</i>	Rho protein kinase inhibitors <i>fasudil</i> (64)(31) <i>netarsudi</i> l(113)(75) <i>ripasudil</i> (109)(71) <i>verosudil</i> (112)(74)
- <i>domide</i>	antineoplastics, thalidomide derivatives <i>avadomide</i> (117)(79) <i>endomide</i> (40)(!) <i>iberdomide</i> (117)(79) <i>lenalidomide</i> (91)(53) <i>mitindomide</i> (70)(34) <i>pomalidomide</i> (97)(59) <i>thalidomide</i> (08)(04)
- <i>dustat</i>	see <i>stat</i>
- <i>ectedin</i>	ecteinascladin derivatives <i>lurbnectedin</i> (105)(67) <i>trabectedin</i> (86)(48)
- <i>ertinib</i>	see -<i>tinib</i>
- <i>espib</i>	heat shock protein (HSP) 90 inhibitors (other than – <i>mycin</i>), antineoplastics <i>ganetespib</i> (105)(67) <i>luminespib</i> (108)(70) <i>onalespib</i> (112)(74)

- <i>estrant</i>	estrogen antagonists <i>brilanestrant</i> (115)(77) <i>elacestrant</i> (115)(77) <i>fulvestrant</i> (79)(40)
- <i>fadine</i>	monoamine transport inhibitors <i>amitifadine</i> (106)(68) <i>bicifadine</i> (43)(43) <i>centanafadine</i> (112)(74)
- <i>farnib</i>	farnesyl transferase inhibitors <i>lonafarnib</i> (86)(48) <i>tipifarnib</i> (86)(48)
- <i>fexor</i>	farnesoid X receptor agonists <i>cilofexor</i> (118) <i>nidufexor</i> (118) <i>turofexorate isopropyl</i> (103)(64) <i>tropifexor</i> (116)(78)
- <i>fibatide</i>	see <i>tide</i>
- <i>fulven</i>	antineoplastic, acylfulvene derivatives <i>irolfulven</i> (85)(45)
- <i>gacestat</i>	see <i>-stat</i>
- <i>ganan</i>	antimicrobial, bactericidal permeability increasing polypeptides <i>iseganan</i> (85)(47) <i>omiganan</i> (89)(51) <i>pexiganan</i> (78)(40)
- <i>gapil</i>	neuronal apoptosis inhibitors, GAPDH <i>omigapil</i> (90)(52)
- <i>golix</i>	gonadotrophin releasing hormone (GnRH) antagonists <i>elagolix</i> (99)(61) <i>linzagolix</i> (118) <i>opigolix</i> (118) <i>relugolix</i> (107)(69) <i>sufugolix</i> (89)(51)
- <i>imepodib</i>	inosine monophosphate dehydrogenase inhibitors <i>merimepodib</i> (87)(47)
- <i>inurad</i>	urate transporter inhibitors <i>dotinurad</i> (116)(78) <i>epaminurad</i> (118) <i>lesinurad</i> (105)(67) <i>verinurad</i> (111)(73)

-ixafor	chemokine CXCR4 antagonists <i>balixafortide</i> (112)(74) <i>burixafor</i> (104)(66) <i>mavorixafor</i> (118) <i>plerixafor</i> (93)(55)
-ixibat	ileal bile acid transporter (IBAT) inhibitors, bile acid reabsorption inhibitors <i>barixibat</i> (88)(50) <i>elobixibat</i> (104)(66) <i>linerixibat</i> (118) <i>maralixibat chloride</i> (113)(75) 10706 <i>odevixibat</i> (for 119) <i>volixibat</i> (113)(75)
-kalner	openers of calcium-activated (maxi-K) K ⁺ -channels <i>flindokalner</i> (86)(48)
-laner	antagonists of GABA (gamma-aminobutyric acid) regulated chloride channels, antiparasitic agents <i>afoxolaner</i> (108)(70) <i>fluralaner</i> (107)(69) <i>lotilaner</i> (110)(72) <i>sarolaner</i> (111)(73) <i>tigolaner</i> (117)(79)
-leptin(e)	leptin derivatives <i>metreleptin</i> (82)(44) <i>zafuleptine</i> (55)(26)
<i>mab</i>	<i>monoclonal antibodies</i>
under targets	
-ami-	serum amyloid protein (SAP)/amyloidosis <i>dezamizumab</i> (115)(77)
-gr(o)-	skeletal muscle mass related growth factors and receptors <i>bimagrumab</i> (100)(70) <i>domagrozumab</i> (114)(76) <i>landogrozumab</i> (113)(75) <i>trevogrumab</i> (113)(75)
-melanotide	<i>see tide</i>
-metinib	<i>see tinib</i>
-moren	non-peptidic growth hormone secretagogues <i>ibutamoren</i> (78)(40)
-nesib	kinesin inhibitors <i>filanesib</i> (109)(71) <i>ispinesib</i> (92)(54) <i>litronesib</i> (101)(63)

-neurin	neurotrophins <i>abrineurin</i> (84)(46)
-nexor	nuclear export inhibitors <i>eltanexor</i> (116)(78) <i>selinexor</i> (110)(72) <i>verdinexor</i> (110)(72)
nil	<i>benzodiazepine receptor antagonists/agonists</i>
-punil	mitochondrial benzodiazepine receptor (MBR)-selective agonists, also partial or inverse (purine derivatives) <i>emapunil</i> (90) <i>Withdrawn</i>
-opran	μ -opioid receptors antagonists <i>axelopran</i> (109)(71) <i>bevenopran</i> (107)(69) <i>ondelopran</i> (106)(68)
To add under (b) category, <i>cefzopran</i> (66)(32)	
To add under (c) category, <i>alvimopan</i> (87)(49)	
-osuran	urotensin receptor antagonists <i>palosuran</i> (91)(53)
-otilate	hepatoprotectants, di(propan-2-yl) 2-(2 <i>H</i> -1,3-dithiol- 2-ylidene)propanedioate and analogues <i>malotilate</i> (44)(21) <i>mivotilate</i> (80)(42)
-parantag	antagonists of heparin and/or low-molecular weight heparins (LMWH) <i>ciraparantag</i> (113)(75) <i>delparantag</i> (108)(70)
-paxar	protease activated receptor type 1 (PAR1) antagonists <i>atopaxar</i> (104)(66) <i>vorapaxar</i> (103)(66)
-pirdine	serotonin receptor antagonists <i>besinirdine</i> (70)(34)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25776

